Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alzheimer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    34 result(s) found for: Alzheimer. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-004474-15 Sponsor Protocol Number: PETFLUTEMETAMOL-FDG/BBRC2015 Start Date*: 2016-03-14
    Sponsor Name:BarcelonaBeta Brain Research Center
    Full Title: Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and of glucose metabolism with 18F-FDG PET in individuals enrolled in the ALFA project
    Medical condition: Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004865 10036654 Prevention LLT
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003362-17 Sponsor Protocol Number: MPC-7869-05-009.02 Start Date*: 2008-01-04
    Sponsor Name:Myriad Pharmaceuticals, Inc
    Full Title: Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects with Dementia of the Alzheimer’s Type
    Medical condition: Treatment of Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Completed) DE (Prematurely Ended) NL (Ongoing) SE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006490-24 Sponsor Protocol Number: CL-758019 Start Date*: 2007-04-19
    Sponsor Name:Neurochem Inc
    Full Title: An Open-Label Extension of the Phase III Study CL-758010 with Alzhemed™ in Patients with Alzheimer’s Disease.
    Medical condition: Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disorder, characterized by gradual cognitive decline, abnormal behaviour, and personality changes.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Ongoing) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002005-19 Sponsor Protocol Number: TTP488-301 Start Date*: 2016-08-19
    Sponsor Name:vTv THERAPEUTICS LLC
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE ...
    Medical condition: MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    20.0 10029205 - Nervous system disorders 10012268 Dementia (excl Alzheimer's type) HLT
    20.0 10029205 - Nervous system disorders 10012296 Dementia of the Alzheimer's type, with depressed mood PT
    20.0 10029205 - Nervous system disorders 10012295 Dementia of the Alzheimer's type, with delusions PT
    20.0 10029205 - Nervous system disorders 10012294 Dementia of the Alzheimer's type, with delirium PT
    20.0 10029205 - Nervous system disorders 10012293 Dementia of the Alzheimer's type, uncomplicated PT
    20.0 10029205 - Nervous system disorders 10012292 Dementia of the Alzheimer's type NOS LLT
    20.0 10029205 - Nervous system disorders 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000799-39 Sponsor Protocol Number: 20-AVP-786-307 Start Date*: 2021-02-05
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q...
    Medical condition: Agitation in patients with dementia of the Alzheimer’s type
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10001499 Agitation mental LLT
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) SK (Trial now transitioned) NL (Ongoing) SI (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002783-88 Sponsor Protocol Number: 331-201-00182 Start Date*: 2018-12-27
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A 12-week, Multicenter, Active-treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheim...
    Medical condition: Agitation Associated With Dementia of the Alzheimer's Type
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) ES (Ongoing) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-021218-50 Sponsor Protocol Number: AB09004 Start Date*: 2011-05-25
    Sponsor Name:AB Science
    Full Title: A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease
    Medical condition: mild to moderate Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012271 Dementia Alzheimer's type LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prohibited by CA) ES (Completed) SK (Prohibited by CA) PL (Completed) GR (Completed) GB (GB - no longer in EU/EEA) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004368-22 Sponsor Protocol Number: 221AD304 Start Date*: 2020-08-26
    Sponsor Name:Biogen Idec Research Limited
    Full Title: Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 an...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) FI (Prematurely Ended) AT (Completed) PL (Completed) PT (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003302-27 Sponsor Protocol Number: ANAVEX2-73-AD-004 Start Date*: 2020-01-22
    Sponsor Name:Anavex Germany GmbH
    Full Title: A Phase 2b/3, Double-Blind, Randomised, Placebo-Controlled 48 week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s Disease (AD).
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002179-21 Sponsor Protocol Number: AB21004 Start Date*: 2022-10-07
    Sponsor Name:AB Science
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib as add-on therapy in patients with mild to moderate Alzhei...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 100000004852 10001896 Alzheimer's disease LLT
    24.1 100000004852 10086384 Early onset Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing) GR (Completed) PL (Prematurely Ended) PT (Prematurely Ended) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003940-19 Sponsor Protocol Number: 331-14-213 Start Date*: 2018-08-06
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo controlled, 2 Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatme...
    Medical condition: Agitation Associated With Dementia of the Alzheimer’s Type
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) ES (Ongoing) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000370-27 Sponsor Protocol Number: COR388-010-UK Start Date*: 2019-10-24
    Sponsor Name:Cortexyme, Inc.
    Full Title: A Randomized, Double-Blind, Placebo Controlled Study of COR388 HCl in Subjects with Alzheimer’s Disease
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000860-10 Sponsor Protocol Number: 10729 Start Date*: 2006-06-30
    Sponsor Name:H. Lundbeck A/S
    Full Title: An Open-Label Study Investigating the Specific Effects of Memantine in Institutionalised Patients with Alzheimer’s Disease
    Medical condition: Effects of memantine treatment in institutionalised patients with Alzheimer's Disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-001515-10 Sponsor Protocol Number: KAR-031 Start Date*: 2022-12-12
    Sponsor Name:Karuna Therapeutics
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease Deme...
    Medical condition: Psychosis Associated with Alzheimer’s Disease Dementia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 100000004873 10037234 Psychosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000307-17 Sponsor Protocol Number: DIAN-TU-001 Start Date*: 2014-01-08
    Sponsor Name:Washington University in St. Louis
    Full Title: A Phase II/III randomized, double-blind, placebo-controlled, cognitive endpoint, multicenter study of potential disease modifying therapies in individuals at risk for and with dominantly inherited ...
    Medical condition: Dominantly Inherited Alzheimer Disease (DIAD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) ES (Temporarily Halted) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004739-58 Sponsor Protocol Number: BAN2401-G000-301 Start Date*: 2019-06-12
    Sponsor Name:Eisai Limited
    Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease
    Medical condition: Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    20.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003733-15 Sponsor Protocol Number: B-003 Start Date*: 2013-11-13
    Sponsor Name:VU University medical center
    Full Title: The Dutch CSF and PET Biomarker Concordance of Alzheimer’s Disease pathology study
    Medical condition: Patients visiting the VUmc Alzheimer Center with objective cognitive complaints or diagnosed with Alzheimer's Disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000933-12 Sponsor Protocol Number: AX-CL-10 Start Date*: 2005-02-22
    Sponsor Name:Axonyx Inc
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease
    Medical condition: Alzheimers disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimers's also affects the levels of a certain neu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001025-31 Sponsor Protocol Number: 2019PI255 Start Date*: 2021-07-29
    Sponsor Name:CHRU Nancy
    Full Title: HIGHLIGHTING THE BENEFITS OF THERAPEUTIC GARDENS IN ALZHEIMER'S DISEASE with 18F-FDG Cerebral PET / CT
    Medical condition: atients followed at the Memory and Research Center (CMRR) and diagnosed with mild to moderate Alzheimer's disease (MMS 15-23)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003558-17 Sponsor Protocol Number: TRx-237-039 Start Date*: 2018-02-25
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of Hydromethylthionine Mesylate (LMTM) Monotherapy in Subjects with Alzheimer's Disease Followed by a 12...
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) PL (Completed) ES (Ongoing) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 19 01:18:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA